A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Berzosertib (Primary) ; Lurbinectedin (Primary)
- Indications Neuroendocrine carcinoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 02 May 2024 Planned number of patients changed from 75 to 120.
- 08 Dec 2023 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 08 Dec 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Aug 2026.